ERBB2 and breast carcinoma: Finally, limited by economic factors, this study only included patients receiving single-target chemotherapy, but failed to show a relationship between TILs, PD-L1+TC, and PD-L1+TILs and the efficacy of neoadjuvant dual-target plus chemotherapy in HER2-positive breast cancer patients.